Please login to the form below
GW Pharma's cannabis-based medicine to be tested in dementia
Trial will be funded by Alzheimer’s Research UK
Merck puts prostate cancer firmly in Keytruda’s sights
Lynparza combination could open up huge new market
Bicycle Therapeutics to tackle AMR with government funding
Biotech to discover new class of antibacterial agents
Gilead lead NASH drug flunks phase 3 test
Analysts suspect the setback could prompt Gilead to license other candidates
Grey Wolf secures £10m Series A to ‘illuminate’ tumour cells
The tech could offer a new treatment paradigm
UniQure edges closer to haemophilia B gene therapy OK
The candidate could free patients from regulator injections of FIX products
Trial dents confidence in Sangamo’s gene-editing tech
Company proposing switch to next-gen version
Galapagos expands presence in fibrosis, NASH with Evotec deal
As lead candidate filgotinib nears filing, firm looks to expand horizons
GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn
Partners to co-develop novel bifunctional fusion protein
Adopting a creative IP approach towards biotech clusters
Why big pharma paradigm needs to change
-
A unique ecosystem How life science and healthcare clusters are driving innovation
-
Riding the wave of digital disruptionThe challenges and rewards of meeting consumer expectations
-
Roche submits Kadcyla for FDA Real-Time reviewAims to extend use in breast cancer patients
-
US, EU regulators back rapid reviews of AZ’s RSV medPositive top-line data triggered speedy assessments
-
Skills shortage and Brexit will hit R&D, warns UK pharmaSkill shortages and Brexit seen as greatest threat
-
Nerve centre gives Novartis edge in clinical trialsAlgorithms predict potential delays
-
Another amyloid bust as Roche pulls crenezumab trialsUndermines amyloid hypothesis hopes. including Biogen candidate
-
Horizon taps academic partner to boost gene editing platformPartners with Rutgers University to license base editing tech
-
GSK and Sanofi join Finland's 500,000 genomics studyAstraZeneca, MSD and Pfizer already participating
-
Lilly appoints Maura Dickler as VP of late phase oncology developmentShe will join the pharma firm from the Memorial Sloan Kettering Cancer Center
-
Metrion Biosciences establishes scientific advisory board
The board will provide scientific oversight and strategic advice to Metrion
-
Dr Sotirios Stergiopoulos leaves Shire for IpsenHe becomes the French biopharma’s chief medical officer
-
Linda Law joins Advicenne as US VP, clinical development and med affairsShe will oversee the biopharma’s developments with its dTRA candidate
-
Dr Fiona Marshall heads up MSD's new UK research facility She will be based in London and focus on early bioscience discovery
Latest research appointments
Featured jobs
-
Digital Account Director
-
Salary TBC
-
Project Manager/ Account Manager
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Salary TBC
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Great salary and benefits
-
Account Director, Medical Education
-
Salary TBC
Subscribe to our email news alerts
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- Cutting through the noise
- AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...
- International Childhood Cancer Day 2019
- The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
- Immuno-oncology in 2019: the rapid evolution continues
- Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Quick links
Infographics
